Trial Profile
Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen: A Prospective, Open, One-arm Clinical Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Feb 2024 Status changed from not yet recruiting to withdrawn prior to enrolment (abandon)
- 11 Jan 2019 Planned End Date changed from 1 Dec 2020 to 1 Feb 2022.
- 11 Jan 2019 Planned primary completion date changed from 1 Sep 2020 to 1 Feb 2020.